609 Broadway NE Albuquerque, NM 87102 Phone: 505-821-0875 Fax: 505-293-1191 Website: www.biomoda.com Biomoda, Inc. Corporate Presentation August 2009

An Albuquerque, New Mexico based medical diagnostics company that has developed an inexpensive, non-invasive, simple, and accurate test for early cancer detection based on a proprietary molecular marker platform. Large unmet medical need Clinical Trial development stage (Phase II) Strong IP portfolio Proven management team Platform for other cancer diagnostic applications Lung – Initial Product Cervical Colorectal Breast

An Albuquerque, New Mexico based medical diagnostics company that has developed an inexpensive, non-invasive, simple, and accurate test for early cancer detection based on a proprietary molecular marker platform.

Large unmet medical need

Clinical Trial development stage (Phase II)

Strong IP portfolio

Proven management team

Platform for other cancer diagnostic applications

Lung – Initial Product

Cervical

Colorectal

Breast

Cancer is the second leading cause of death by disease in the U.S. CDC: Cancer: 559,888 Lung cancer Leading cause of cancer deaths 60% of lung cancer patients die within one year of diagnosis Most expensive cancer to treat (1) ELCAP Study New England Journal of Medicine (2006)

Cancer is the second leading cause of death by disease in the U.S. CDC: Cancer: 559,888

Lung cancer

Leading cause of cancer deaths

60% of lung cancer patients die within one year of diagnosis

Most expensive cancer to treat

In 2007, cancer was responsible for an estimated 7.6 million deaths worldwide World Health Organization predicts 50% rise in cancer incidence by year 2020 Source: B.B.C. Media UK

In 2007, cancer was responsible for an estimated 7.6 million deaths worldwide

World Health Organization predicts 50% rise in cancer incidence by year 2020

No Screening Protocol Available Patient tested only when symptoms are present: Resulting in Stage III-IV diagnosis 15% 5 year survival rate

T hanks to significant federal and state investments over the past 35 years in research and early detection, the 5 year survival rates for breast, prostate and colon cancers are now 87%, 99% and 65% respectively. Lung cancer remains at 15% Senate Resolution to fund Lung Cancer screening May 2006 because survivability has not improved ELCAP study NEJM October 2006 Identifying LC in Stage 1 increase 5 year 15% to 92% Altering course of care/therapy routes Resection Pathway inhibitors: defined through genomics Radiology/Chemo-therapy Lifestyle changes: smoking cessation

T hanks to significant federal and state investments over the

past 35 years in research and early detection, the 5 year

survival rates for breast, prostate and colon cancers are

now 87%, 99% and 65% respectively.

Lung cancer remains at 15%

Senate Resolution to fund Lung Cancer screening May

2006 because survivability has not improved

ELCAP study NEJM October 2006

Identifying LC in Stage 1 increase 5 year 15% to 92%

Altering course of care/therapy routes

Resection

Pathway inhibitors: defined through genomics

Radiology/Chemo-therapy

Lifestyle changes: smoking cessation

Technology originally developed at Los Alamos National Laboratory TCPP preferentially binds to cancer cells and fluoresces red when excited with UV light 5, 10, 15, 20 Tetrakis (Carboxyphenyl) Porphine

Technology originally developed at Los Alamos National Laboratory

Deep Lung sputum sample collected using the Lung Flute Sample collected into a sterile collection cup Sample transported to lab at room temperature

Deep Lung sputum sample collected using the Lung Flute

Sample collected into a sterile collection cup

Sample transported to lab at room temperature

Sample processed onto a microscope slide using ThinPrep 2000 slide processor Processor makes a monolayer of subjects cells onto microscope slide

Sample processed onto a microscope slide using ThinPrep 2000 slide processor

Processor makes a monolayer of subjects cells onto microscope slide

Slide is incubated in CyPath® labeling solution Slide is then prepared for viewing under microscope

Slide is incubated in CyPath® labeling solution

Slide is then prepared for viewing under microscope

New device that provides accurate image captures and enhanced data set Eliminates background florescence and other noise Captures at the subcellular, cellular and tissue level

New device that provides accurate image captures and enhanced data set

Eliminates background florescence and other noise

Captures at the subcellular, cellular and tissue level

Cancer Normal

Cancer

Normal

100% specificity (12/12) 100% sensitivity (15/15) Blind Sample Number of Patients Number of positive red Fluorescent cells Normals 12 0 Lung Cancer 15 15

Unique Dataset Collected Participant Modality Comparison: CT scan/read PAP cytology analysis CyPath® results Data from 125 participants compiled Longitudinal Component Started Follow-up 3, 6, 9, & 12 month

Unique Dataset Collected

Participant Modality Comparison:

CT scan/read

PAP cytology analysis

CyPath® results

Data from 125 participants compiled

Longitudinal Component Started

Follow-up 3, 6, 9, & 12 month

$1.65 million appropriated by NM State Legislature to screen military veterans for early stage lung cancer Screening tool is Biomoda’s proprietary CyPath ® assay

$1.65 million appropriated by NM State Legislature to screen military veterans for early stage lung cancer

Screening tool is Biomoda’s proprietary CyPath ® assay

Currently completing Phase 2 clinical trial Phase 3: Multi-site; up to 3500 participants End point: 50 asymptomatic Lung Cancer FDA submission; 9 months to approval

Currently completing Phase 2 clinical trial

Phase 3: Multi-site; up to 3500 participants

End point: 50 asymptomatic Lung Cancer

FDA submission; 9 months to approval

Reimbursement: there are CPT codes for the various components of the test that are already approved CPT coding study: $75 - $175 Biomoda estimate: $100 per test COGS 50%: lab overhead; supplies; analytics

Reimbursement: there are CPT codes for the various components of the test that are already approved

CPT coding study: $75 - $175

Biomoda estimate: $100 per test

COGS 50%: lab overhead; supplies; analytics

Stage 1 – Internal Testing Revenue driven via single use components Peer Review Journal Articles and Study Reports Poster Sessions and Medical Conference Presentations Contract Sales force to “detail” doctors Stage II – Out License Strategic Alliance with Regional/National Labs Licensing of Clinical Labs - Quest, Labcorp, etc. to do testing. Expansion to machine testing to reduce cost

Stage 1 – Internal Testing

Revenue driven via single use components

Peer Review Journal Articles and Study Reports

Poster Sessions and Medical Conference Presentations

Contract Sales force to “detail” doctors

Stage II – Out License

Strategic Alliance with Regional/National Labs

Licensing of Clinical Labs - Quest, Labcorp, etc. to do testing.

Expansion to machine testing to reduce cost

Government sales: US Veterans Administration Active military FDA approval: Sales to general public as annual screening test (like PAP and PSA tests) European and Japanese markets Similar staged strategy for other cancers: cervical, bladder, colorectal, & breast

Government sales:

US Veterans Administration

Active military

FDA approval:

Sales to general public as annual screening test (like PAP and PSA tests)

European and Japanese markets

Similar staged strategy for other cancers:

cervical, bladder, colorectal, & breast

John J. Cousins - President and CEO 25 years experience starting as an electronics engineer up to his current role as executive and Entrepreneur. MBA from The Wharton School and undergraduate degrees from Boston University and MIT Tim Zannes - General Counsel University of North Carolina and the University of New Mexico where he earned his J.D. degree Constance Dorian - Vice President of Technical Operations 20 years experience in the design and development of In Vitro diagnostic assays, clinical studies, quality control, quality assurance, product support programs, product improvement programs, cost reduction programs, contract negotiations, inventory control, and production planning following FDA Guidelines B.S. in Biology from San Diego State University Angela Martinez Cancer Research Associate B.S. in Biology and a B.A. in Spanish from the University of New Mexico. She is currently working towards an M.S. in Health Education. Her experiences lie in the coordination, conduction, and analysis of environmental and clinical research Gordon Bennett - Fluorescence/Biophotonics Microscopist B.S. in physics as well as a J.D. from UNM. His background is in photonics and electronics. He has been adjunct faculty at the College of Santa Fe and has held the Chair in Photonics and Biophotonics at CNM. He is currently a member of the Optical Society of America and the New Mexico State Bar. Verrity Gershin - Corporate Secretary & Director of Administration Bachelors degree from the University of New Mexico Eleven years of experience in accounting and SEC filings

John J. Cousins - President and CEO

25 years experience starting as an electronics engineer up to his current role as executive and

Entrepreneur.

MBA from The Wharton School and undergraduate degrees from Boston University and MIT

Tim Zannes - General Counsel

University of North Carolina and the University of New Mexico where he earned his J.D. degree

Constance Dorian - Vice President of Technical Operations

20 years experience in the design and development of In Vitro diagnostic assays, clinical studies,

quality control, quality assurance, product support programs, product improvement programs, cost

reduction programs, contract negotiations, inventory control, and production planning following FDA

Guidelines

B.S. in Biology from San Diego State University

Angela Martinez Cancer Research Associate

B.S. in Biology and a B.A. in Spanish from the University of New Mexico. She is currently working

towards an M.S. in Health Education. Her experiences lie in the coordination, conduction, and analysis

of environmental and clinical research

Gordon Bennett - Fluorescence/Biophotonics Microscopist

B.S. in physics as well as a J.D. from UNM. His background is in photonics and electronics. He has been

adjunct faculty at the College of Santa Fe and has held the Chair in Photonics and Biophotonics at CNM. He is

currently a member of the Optical Society of America and the New Mexico State Bar.

Verrity Gershin - Corporate Secretary & Director of Administration

Bachelors degree from the University of New Mexico

Eleven years of experience in accounting and SEC filings

John J. Cousins – President, CEO, & Director Maria Zannes - Director 30 years experience in the environmental and energy industries—from federal lobbyist to company president. Formerly the president of the national waste-to-energy trade group in Washington, D.C., Ms. Zannes currently consults for private clients in the medical and environmental industries Ms. Zannes is licensed to practice law in Washington State and New Mexico David Lambros - Director Practiced law for more than 25 years and served on various boards, including Commerce Exchange Bank and Southwest General Hospital. David presently is a director on the Systems Board at Southwest General Hospital, a multi-million dollar company Lewis White - Director Director and CEO of New Energies Nebraska, LLC, a subsidiary of Standard Alcohol Company

John J. Cousins – President, CEO, & Director

Maria Zannes - Director

30 years experience in the environmental and energy industries—from federal lobbyist to company president. Formerly the president of the national waste-to-energy trade group in Washington, D.C., Ms. Zannes currently consults for private clients in the medical and environmental industries

Ms. Zannes is licensed to practice law in Washington State and New Mexico

David Lambros - Director

Practiced law for more than 25 years and served on various boards, including Commerce Exchange Bank and Southwest General Hospital. David presently is a director on the Systems Board at Southwest General Hospital, a multi-million dollar company

Lewis White - Director

Director and CEO of New Energies Nebraska, LLC, a subsidiary of Standard Alcohol Company

Thomas Bauer, MD- Chief of Thoracic Surgery, Graham Cancer Center, U of Delaware Dan Merrick , MD- Chief Cytopathologist, VAMC Denver Tim Kennedy, MD- Pathologist, U of Colorado Lara Patriquin, MD- Chief of CT Radiology, RAA Ramesh Gopal, MD- Chief of Radiology Oncology, MD Anderson Steve Groshang, MD PhD- Pathologist, Head of Pathology Laboratories, National Jewish Health Marty Jacobson, PhD- Saccommanno Institute R & D

Thomas Bauer, MD- Chief of Thoracic Surgery, Graham Cancer Center, U of Delaware

Dan Merrick , MD- Chief Cytopathologist, VAMC Denver

Tim Kennedy, MD- Pathologist, U of Colorado

Lara Patriquin, MD- Chief of CT Radiology, RAA

Ramesh Gopal, MD- Chief of Radiology Oncology, MD Anderson

Steve Groshang, MD PhD- Pathologist, Head of Pathology Laboratories, National Jewish Health

Marty Jacobson, PhD- Saccommanno Institute R & D

Symbol: BMOD (trades on OTC Bulletin Board) Recent Price: $0.30 Shares Outstanding: 77.5 million Market Capitalization: $23 million Revenue Projections: Unit Sales Revenue Year 2010 2011 2012 2013 2014 US – Lung 10,000 130,000 200,000 250,000 312,500 Europe - Lung 80,000 200,000 250,000 312,500 Japan – Lung 20,000 120,000 150,000 187,500 Total 10,000 230,000 520,000 650,000 812,500 $ Rev. @ $100/Test $1.0 M $23.0 M $52.0 M $65.0 M $81.25 M

609 Broadway NE Albuquerque, NM 87102 Phone: 505-821-0875 Fax: 505-293-1191 Website: www.biomoda.com Thank You